PMZ 1620

Drug Profile

PMZ 1620

Alternative Names: IRL-1620; PMZ-1620; SPI-1620

Latest Information Update: 04 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Pharmazz; Spectrum Pharmaceuticals
  • Class Antineoplastics; Peptides; Vasodilators
  • Mechanism of Action Angiogenesis inducing agents; Diagnostic imaging enhancers; Endothelin B receptor agonists; Neurogenesis stimulants; Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke
  • Clinical Phase Unknown Solid tumours
  • Preclinical Cerebrovascular disorders; Neurodegenerative disorders
  • Discontinued Biliary cancer; Non-small cell lung cancer

Most Recent Events

  • 30 Mar 2018 Pharmazz receives patent allowance for PMZ 1620 in Canada
  • 11 Jan 2018 Pharmazz plans studies for Amyotrophic lateral sclerosis
  • 28 Nov 2017 Pharmazz has patent protection for PMZ 1620 in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top